UNSPSC 51361938: Phenobarbital sodium

This classification denotes a barbiturate and anticonvulsant agent with the molecular formula C12H11N2O3.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier SW9M9BB5K3, chemically known as 2,4,6(1h,3h,5h)-pyrimidinetrione, 5-ethyl-5-phenyl- but more generally known as phenobarbital sodium, which bears US NIH Compound Identifier 4763. European Medicines Agency schedules Phenobarbital sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09771MIG.

UNSPSC 51361938 Phenobarbital sodium is a Commodity code for a controlled barbiturate pharmaceutical with limited recent state and local procurement activity under this specific code. Recent solicitations show state and local governments using related pharmaceutical codes to procure naloxone, generic multi-source pharmaceuticals, and OTC products through centralized distribution channels rather than individual barbiturate purchases. Issuing bodies include county health departments, state HHS agencies, and multistate cooperative purchasing alliances that aggregate demand across multiple jurisdictions and government facilities. The work involves establishing supply contracts with drug manufacturers and authorized wholesalers, with vendors required to maintain FDA compliance, cGMP certification, supply chain security certifications, and specific insurance coverage thresholds.

Geographic activity spans Florida, Texas, and the Minnesota-led multistate cooperative purchasing network (including Oregon). Representative recent opportunities include Seminole County, Florida's IFB for naloxone and drug deactivation systems (posted June 30, 2026; due July 26, 2023) requesting 1,900 units of naloxone annually with quarterly deliveries; Texas Health and Human Services Commission's RFI for direct-to-manufacturer prescription programs (posted April 3, 2026; response deadline April 3, 2026) exploring vendor capacity for therapeutic pharmacy initiatives; and the Minnesota Multistate Cooperative Purchasing Alliance's RFP for generic multi-source pharmaceuticals and OTC products (posted January 20, 2026; due March 26, 2026) with awards effective July 1, 2026, requiring vendors to work through three authorized wholesalers and meet a 3 percent administrative fee structure. Vendor evaluation emphasizes price competitiveness (75 percent weighting in the MMCAP RFP), compliance with federal drug security and manufacturing standards, EDI capability, and insurance certifications.